» Articles » PMID: 28796913

Patients with Psoriasis Have Different Preferences for Topical Therapy, Highlighting the Importance of Individualized Treatment Approaches: Randomized Phase IIIb PSO-INSIGHTFUL Study

Overview
Date 2017 Aug 11
PMID 28796913
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Poor adherence to topical therapy in psoriasis remains an issue; it is associated with poor clinical outcomes, reduced quality of life and increased costs. Treatment-related factors leading to poor adherence include lack of efficacy, excessive time applying medication and poor cosmetic characteristics (e.g. slow absorption, greasiness).

Objective: To assess the topical treatment attributes that influence patient preference for fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0.5 mg/g as dipropionate (BD) foam vs. gel, as well as in comparison with the latest topical treatment (LTT) a patient received.

Methods: PSO-INSIGHTFUL was a Phase IIIb, prospective, multicentre (Canada/Germany), open-label, randomized, two-arm crossover study in patients aged ≥18 years with mild-to-severe psoriasis (NCT02310646). Following a washout period of up to 4 weeks, patients were randomized 1 : 1 to once-daily Cal/BD foam for 1 week, followed by Cal/BD gel for 1 week, or vice versa. Patients completed six questionnaires evaluating patient preferences.

Results: A total of 213 patients were randomized; 118 had received a topical treatment in the previous 3 months. Based on the Subject's Preference Assessment, 50% of patients preferred Cal/BD foam and 50% preferred Cal/BD gel. Based on the Topical Product Usability Questionnaire (TPUQ), overall mean scores were high for both Cal/BD foam and gel, and were often significantly in favour of both products compared with LTT. Greater differences between Cal/BD foam and gel vs. LTT occurred when the previous treatment was an ointment or cream. Cal/BD foam was generally preferred by younger patients (aged 18-39 years), whereas Cal/BD gel tended to be preferred by older patients (aged ≥40 years). Results from other questionnaires were aligned with the TPUQ.

Conclusions: Patients with psoriasis have diverse needs and different preferences for topical treatment. This knowledge may help prescribers to choose the right formulation for the right patient, potentially leading to improved adherence and better treatment outcomes.

Citing Articles

Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older.

Kedra K, Reich A Drug Des Devel Ther. 2024; 18:5827-5839.

PMID: 39670279 PMC: 11636291. DOI: 10.2147/DDDT.S240867.


Exploring the Correlation between the PASI and DLQI Scores in Psoriasis Treatment with Topical Ointments Containing Mill. Extract.

Gavra D, Kosa D, Peto A, Jozsa L, Ujhelyi Z, Feher P Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204197 PMC: 11359679. DOI: 10.3390/ph17081092.


Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids.

Gisondi P, Gracia-Cazana T, Kurzen H, Galvan J J Clin Med. 2024; 13(15).

PMID: 39124750 PMC: 11313259. DOI: 10.3390/jcm13154484.


Unveiling the potential of photodynamic therapy with nanocarriers as a compelling therapeutic approach for skin cancer treatment: current explorations and insights.

Mohanty S, Desai V, Jain R, Agrawal M, Dubey S, Singhvi G RSC Adv. 2024; 14(30):21915-21937.

PMID: 38989245 PMC: 11234503. DOI: 10.1039/d4ra02564d.


Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patients with Psoriasis.

Jalili A, Thoning H, Jablonski Bernasconi M, Papp K Acta Derm Venereol. 2024; 104:adv12623.

PMID: 38327215 PMC: 10865104. DOI: 10.2340/actadv.v104.12623.


References
1.
Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L . Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 3:61-7. DOI: 10.1111/j.1468-3083.2012.04525.x. View

2.
Lebwohl M, Tyring S, Bukhalo M, Alonso-Llamazares J, Olesen M, Lowson D . Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. J Clin Aesthet Dermatol. 2016; 9(2):34-41. PMC: 4771388. View

3.
Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

4.
Zaghloul S, Goodfield M . Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004; 140(4):408-14. DOI: 10.1001/archderm.140.4.408. View

5.
Menter A, Gold L, Bukhalo M, Grekin S, Kempers S, Boyce B . Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013; 12(1):92-8. View